Emergency: +47 91502770 / mail: solidact@ous-hf.no



EU SOLIDACT

Part of EU-RESPONSE

Inclusion criteria:

- ≥ 18 years
- Hospitalized
- SARS CoV2 PCR positive
- Severe/ critical COVID-19 with:
  - SpO_2<90% room air, **or**
  - SpO_2 90-94% with downwards trend/ signs of respiratory distress, **or**
  - Need of oxygen by NIV (CPAP, BIPAP), high flow or non-rebreather mask, **or**
  - Need of mechanical ventilation/ECMO
- Informed consent

Exclusion criteria:

- Pregnancy/ breastfeeding
- Transfer to non-trial site within 72 hours
- Current cytotoxic/ biologic therapy without washout period
- Prednisone/ (equiv.) >20 mg daily for ≥14 days before screening
- Dexamethasone 6 mg daily for > 4 days
- Current OAT3-inhibitor use
- COVID-related symptoms > 14 days/ hospitalized > 7 days
- **Live** vaccine ≤ 4 weeks before screening/ during study
- Current/ planned Extracorporeal Blood Purification
- Active TB/ latent TB treated < 4 weeks
- Active critical infection
- Active malignancy
- VTE/ DVT/ PE < 12 weeks before screening/ recurrent VTE/ DVT/ PE
- Absolute Neutrophil Count <1000 cells/ microliters
- Absolute Lymphocute Count <200 cells/microliters
- AST/ ALT >5 times Upper Limit of Normal
- eGFR <15 mL/min/1.73 m^2
- Hypersensitivity to baricitinib/ constituents
- In another COVID-19 clinical trial